GIDS Research Radar · Vaccine safety https://globalinfectiousdisease.com/research/ Published infectious-disease literature filtered to Vaccine safety. en Wed, 09 Sep 2026 07:02:01 GMT Post-marketing safety surveillance of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine: a disproportionality analysis of the vaccine adverse event reporting system (2015–2025) https://globalinfectiousdisease.com/research/articles/10-3389-fcimb-2026-1831548-a72456c2/ https://globalinfectiousdisease.com/research/articles/10-3389-fcimb-2026-1831548-a72456c2/ Tue, 08 Sep 2026 00:00:00 GMT The paper addresses post-marketing vaccine safety surveillance for a routinely recommended vaccine. Its relevance is strongest for safety signal detection and hypothesis generation in Tdap vaccination programs. Pertussis Diphtheria Tetanus Vaccination Surveillance Vaccine safety Journal article Strengthening public understanding and prevention of dengue in Malaysia: insights and recommendations based on knowledge, attitudes, and practices toward vector control and vaccination https://globalinfectiousdisease.com/research/articles/10-3389-fpubh-2026-1807183-3086719d/ https://globalinfectiousdisease.com/research/articles/10-3389-fpubh-2026-1807183-3086719d/ Thu, 20 Aug 2026 00:00:00 GMT Identifying specific informational gaps and behavioral barriers supports the development of focused outreach initiatives. Aligning communication strategies with established community trust networks could enhance engagement with integrated disease management approaches. Dengue COVID-19 Vaccination Transmission dynamics Vaccine safety Cross-sectional study Determinants of the Seasonal Influenza Vaccination Uptake Among People Aged 50 Years or Above During and After the Pandemic: A Systematic Review https://globalinfectiousdisease.com/research/articles/10-3390-vaccines14080705-edd7b616/ https://globalinfectiousdisease.com/research/articles/10-3390-vaccines14080705-edd7b616/ Sat, 15 Aug 2026 00:00:00 GMT The synthesized data offers practical guidance for structuring future immunization initiatives and allocating resources to improve coverage in older adult populations. Influenza SARS COVID-19 Vaccination Vaccine safety Systematic review Real-world analysis of depression-related adverse events associated with the adsorbed anthrax vaccine: integrating pharmacovigilance signals, machine learning risk prediction, and transcriptomic mechanisms https://globalinfectiousdisease.com/research/articles/10-1186-s40249-026-01483-0-c4194a40/ https://globalinfectiousdisease.com/research/articles/10-1186-s40249-026-01483-0-c4194a40/ Mon, 10 Aug 2026 00:00:00 GMT The documented reporting patterns indicate a rationale for strengthening psychiatric symptom tracking during post-vaccination windows and refining safety communications within biodefense preparedness programs. Anthrax Vaccination Vaccine safety Treatment One Health Journal article V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023 https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128725-c1232c3d/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128725-c1232c3d/ Sat, 01 Aug 2026 00:00:00 GMT Continuous tracking of self-reported tolerability complements traditional clinical trial metrics and supports ongoing evaluation of emerging immunization products. Identifying engagement drop-offs informs strategy development for sustaining participant involvement during future public health emergencies. COVID-19 SARS Vaccination Surveillance Vaccine safety Journal article Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022–2023 https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128821-769efdf1/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128821-769efdf1/ Sat, 01 Aug 2026 00:00:00 GMT Contemporaneous incidence estimates for 30 safety outcomes across five organ systems can inform benefit-risk framing for new and existing respiratory vaccines during the COVID-19 endemic era and highlight the need to account for age and sex when interpreting expected rates. COVID-19 Influenza SARS Vaccination Surveillance Vaccine safety Cohort study Cross-sectional analysis of chikungunya vaccine acceptability among residents of Ponce, Puerto Rico, 2024–2025 https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128845-e5eb952d/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128845-e5eb952d/ Sat, 01 Aug 2026 00:00:00 GMT Identifying regional vaccination preferences enables health authorities to develop targeted educational campaigns that address safety inquiries and potentially increase immunization coverage during future arboviral events. Chikungunya Vaccination Outbreak investigation Vaccine safety Cross-sectional study COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high vaccine uptake for the next pandemic https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128912-61c4c107/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128912-61c4c107/ Sat, 01 Aug 2026 00:00:00 GMT Sustaining elevated protection levels in this clinical subgroup requires targeted communication strategies that address safety perceptions and counteract inaccurate health information. COVID-19 AIDS Vaccination Vaccine safety Treatment Cohort study The institutional roots of vaccine uptake and hesitancy: evidence from Africa https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128980-e3b13350/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128980-e3b13350/ Sat, 01 Aug 2026 00:00:00 GMT The findings suggest that improving vaccination rates in Africa requires both strengthened governance and credible vaccine communication as complementary interventions, given that institutional factors represent significant demand-side barriers even when vaccine supply is adequate. COVID-19 SARS Vaccination Vaccine safety Journal article mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128630-6d3ff677/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128630-6d3ff677/ Mon, 01 Jun 2026 00:00:00 GMT The findings provide Canadian adult vaccine-safety evidence on short-term health events following two-dose mRNA vaccination and include comparison with an unvaccinated group. The abstract describes symptom frequency and healthcare-utilization outcomes but does not establish longer-term effects or causality. COVID-19 SARS Vaccination Vaccine safety Surveillance Cohort study MVA-BN monkeypox vaccine safety in a clinical trial in the Democratic Republic of the Congo https://globalinfectiousdisease.com/research/articles/10-1038-s41541-026-01490-0-faf40751/ https://globalinfectiousdisease.com/research/articles/10-1038-s41541-026-01490-0-faf40751/ Thu, 28 May 2026 00:00:00 GMT The findings provide additional evidence from an endemic setting that the MVA-BN vaccine, widely deployed for monkeypox prevention, is generally safe and well-tolerated with predominantly mild injection site reactions. Monkeypox Vaccination Treatment Vaccine safety Journal article Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2025-128016-0888af7f/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2025-128016-0888af7f/ Thu, 01 Jan 2026 00:00:00 GMT Findings inform clinical guidance on revaccination after cardiac AEFIs, suggesting revaccination may be considered for chest pain not meeting myocarditis criteria while indicating caution for adults with prior myopericarditis. COVID-19 SARS Vaccination Vaccine safety Journal article Vaccination perspectives: the Qdenga® dilemma https://globalinfectiousdisease.com/research/articles/10-1093-jtm-taaf023-f46fe8f2/ https://globalinfectiousdisease.com/research/articles/10-1093-jtm-taaf023-f46fe8f2/ Sun, 09 Mar 2025 00:00:00 GMT The paper is relevant to travel medicine because it discusses how Qdenga is considered in vaccine decision-making for travellers. It also highlights the need for careful interpretation of evolving guidance and evidence. Dengue Vaccination Travel medicine Vaccine safety Journal article The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC’s COVID-19 pandemic response https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-12-031-cba5f22c/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-12-031-cba5f22c/ Wed, 01 Feb 2023 00:00:00 GMT The system contributed to CDC vaccine safety assessments for FDA-authorized COVID-19 vaccines and may serve as a model for future pandemic response activities and novel vaccine rollouts in non-pandemic contexts. COVID-19 Vaccination Vaccine safety Surveillance Journal article Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020 https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-11-003-873888a8/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-11-003-873888a8/ Sun, 01 Jan 2023 00:00:00 GMT The findings provide historical incidence-rate context for comparing post-vaccination adverse event rates within the same database. The abstract emphasizes the need to account for demographic and temporal variation when interpreting such comparisons. COVID-19 Vaccination Surveillance Vaccine safety Journal article Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-11-069-042e9b45/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-11-069-042e9b45/ Sun, 01 Jan 2023 00:00:00 GMT The findings contribute to the safety knowledge base for COVID-19 vaccination in elderly populations and may inform decision making by government agencies, healthcare providers, and the public. FDA stated that potential benefits of COVID-19 vaccination outweigh potential risks of COVID-19 infection. COVID-19 SARS Influenza Vaccination Surveillance Vaccine safety Journal article A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-06-006-6f3ef0e0/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-06-006-6f3ef0e0/ Mon, 01 Aug 2022 00:00:00 GMT Inactivated viral vaccine technology has been applied to diseases of global health threat, and this chikungunya vaccine candidate offers an effective, flexible system for high-yield manufacturing with favorable stability for distribution. Chikungunya COVID-19 SARS Poliomyelitis Influenza Treatment Vaccination Vaccine safety Journal article Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2200674-3e7524b3/ https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2200674-3e7524b3/ Thu, 19 May 2022 00:00:00 GMT The trial provides randomized evidence that a third BNT162b2 dose given roughly 10–11 months after the primary series had an acceptable short-term safety profile and substantially reduced Covid-19 incidence relative to two doses during a median 2.5-month follow-up, informing booster-dose decision-making. SARS COVID-19 Vaccination Treatment Vaccine effectiveness Vaccine safety Randomised controlled trial Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022 https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7109e2-7a579004/ https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7109e2-7a579004/ Fri, 04 Mar 2022 00:00:00 GMT The findings support provider and public counseling that local and systemic reactions should be expected after adolescent booster vaccination, while serious adverse events remain rare. This information is relevant for informed consent and vaccine confidence in the adolescent population. COVID-19 SARS Vaccination Surveillance Vaccine safety Journal article Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 https://globalinfectiousdisease.com/research/articles/10-1001-jama-2021-24110-9995877c/ https://globalinfectiousdisease.com/research/articles/10-1001-jama-2021-24110-9995877c/ Tue, 25 Jan 2022 00:00:00 GMT The authors note that the elevated myocarditis risk should be interpreted alongside the established benefits of COVID-19 vaccination, suggesting relevance for vaccine-safety communication and risk-benefit framing. COVID-19 Vaccination Surveillance Vaccine safety Diagnostics Treatment Journal article COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2021-11-094-d3bf0be6/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2021-11-094-d3bf0be6/ Sat, 01 Jan 2022 00:00:00 GMT The abstract provides evidence about vaccine perceptions and uptake patterns in an essential-worker cohort, including differences by occupation, prior infection, and initial vaccine intention. It also reports changes in vaccine-related responses between survey administrations, which may be relevant to research on vaccine acceptance in similar populations. SARS COVID-19 Vaccination Vaccine effectiveness Outbreak investigation Vaccine safety Cohort study Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis https://globalinfectiousdisease.com/research/articles/10-1186-s40249-021-00915-3-1cc96722/ https://globalinfectiousdisease.com/research/articles/10-1186-s40249-021-00915-3-1cc96722/ Sun, 14 Nov 2021 00:00:00 GMT The findings support accelerating vaccination and improving coverage as a critical strategy to reduce COVID-19 deaths, severe cases, symptomatic infections, and transmission in the context of ongoing variant emergence. SARS COVID-19 Vaccination Outbreak investigation Surveillance Vaccine effectiveness Vaccine safety Systematic review From program suspension to the pandemic: A qualitative examination of Australia’s vaccine pharmacovigilance system over 10 years https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2021-07-059-bee48e86/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2021-07-059-bee48e86/ Wed, 01 Sep 2021 00:00:00 GMT The findings address readiness for COVID-19 vaccine safety monitoring and identify opportunities to enhance pharmacovigilance systems that could contribute to both local and global vaccine safety surveillance. Transparent communication was emphasized as essential for addressing vaccine safety concerns during the pandemic. COVID-19 Influenza SARS Vaccination Surveillance Vaccine safety Journal article Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2014-11-017-6493b53f/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2014-11-017-6493b53f/ Thu, 01 Jan 2015 00:00:00 GMT The findings indicate that myth-correction approaches to influenza vaccine promotion may have unintended effects among subgroups most concerned about side effects, and the authors suggest this may not be an effective strategy for increasing immunization. Influenza Vaccination Treatment Vaccine safety Climate and environment Journal article Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2013-09-063-bb30bea6/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2013-09-063-bb30bea6/ Sun, 01 Dec 2013 00:00:00 GMT The authors interpret the re-arranged evidence as supporting policies to vaccinate elderly people against influenza and as providing substantial evidence that vaccination can reduce infection and related disease and death in this group. Influenza Health policy Vaccination Vaccine effectiveness Vaccine safety Climate and environment Meta-analysis Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans https://globalinfectiousdisease.com/research/articles/10-1093-cid-cis327-f0956a5e/ https://globalinfectiousdisease.com/research/articles/10-1093-cid-cis327-f0956a5e/ Thu, 22 Mar 2012 00:00:00 GMT The vaccine targets conserved internal antigens shared across all influenza A subtypes, suggesting potential for broad protection against multiple strains not covered by current seasonal vaccines. Influenza Vaccination Treatment Vaccine safety Journal article